| Bruker Corp–Leucadia: investor conference, 201906 supply service Bruker presents at Jefferies Healthcare Conference in New York |
2019-06-06 |
| Evotec–Leucadia: investor conference, 201906 supply service Evotec AG presents at Jefferies 2019 Global Healthcare Conference NYC |
2019-06-06 |
| Evotec–Deutsche Bank: investor conference, 201906 supply service Evotec presents at dbAccess Berlin Conference |
2019-06-05 |
| Medigene–Leucadia: investor conference, 201906 supply service Medigene presents at Jefferies Global Healthcare Conference NY |
2019-06-04 |
| Bayer–Roche: molecular companion diagnostics, 201905– collab ww €na developm + commercialisation o fNGS-based CDx in oncology |
2019-05-29 |
| Biocrates–NONE: investment, 201905– bankruptcy filed for subsidiary Metanomics Health GmbH |
2019-05-22 |
| Cubuslab–Labfolder: investment, 201905 acquisition merger of Cubuslab Gmbh + Labfolder GmbH + new name Labforward GmbH |
2019-05-22 |
| Adrenomed–Informa: investor conference, 201905 supply service Adrenomed presents at BioEquity Europe 2019 in Barcelona |
2019-05-20 |
| Just Biotherapeutics (US)–Evotec: investment, 201905– acquisition 100% for $60m upfront + $30m upfront |
2019-05-20 |
| Storm Therapeutics–SEVERAL: investment, 201905 financing round Series A extension £14m bringing total round to £30m incl new investor Seroba LS |
2019-05-20 |
| Waters–UBS: investor conference, 201905 supply service Waters presents at UBS Global Healthcare Conference NY |
2019-05-20 |
| DNA Script–SEVERAL: investment, 201905 financing round Series B $38.5m led by LSP |
2019-05-16 |
| Inovio–Qiagen: molecular companion diagnostics, 201905– collab developm of CDx for VGX-3100 DNA-based immunotherapy for cervical dysplasia |
2019-05-16 |
| Roche–AbbVie: ventoclax, 201905 collab existent joint commercialisation in US as Venclexta by AbbVie + Genentech |
2019-05-16 |
| Philogen–SEVERAL: investment, 201905 financing round €62m from existing + new private investors |
2019-05-13 |
| TreeFrog Therapeutics–SEVERAL: investment, 201905 financing round Series A €6.5m led by XAnge + incl Galia Geston et al |
2019-05-13 |
| MabVax Therapeutics–BioNTech: investment, 201905 acquisition €na of antibody assets + infrastructure + lab equipment in San Diego |
2019-05-08 |
| Therachon–Pfizer: investment, 201905– acquisition 100% $340m upfront + $470m milestones excl apraglutide development program |
2019-05-08 |
| Cutech (IT)–Symrise: investment, 201905 acquisition of Cutech Srl by Symrise |
2019-05-06 |
| miRdetect–SEVERAL: investment, 201905 seed financing round 7-digit € from HTGF + BBM Bremen + a private investor |
2019-05-02 |
| Alentis Therapeutics–SEVERAL: investment, 201904 financing round Series A CHF12.5m co-led by BioMedPartners + BB Pureos Bioventures |
2019-04-30 |
| SGS–Veeva Systems: clinical research software, 201904– supply global implementation of Veeva Vault CTMS by SGS |
2019-04-30 |
| Zellkraftwerk–Canopy Biosciences: investment, 201904 acquisition of Zellkraftwerk GmbH by Canopy Biosciences |
2019-04-29 |
| ADC Therapeutics–Adagene: antibody technology, 201904– collab + license agreem €na using SAFEbody technology for ADC development |
2019-04-24 |
| Poseida Therapeutics–Novartis: investment, 201904 financing round Series C totalling $142m incl $75m from lead investor Novartis Pharma AG |
2019-04-22 |
| Poseida Therapeutics–SEVERAL: investment, 201904 financing round Series C $142m led by Novartis with $75m |
2019-04-22 |
| Arrakis Therapeutics–SEVERAL: investment, 201904 financing round Series B $75m co-led by VenBio Partners + Nextech Invest |
2019-04-18 |
| Bruker Corp–Univ Nijmegen: mass spectrometry, 201904– collab establishment of joint Center of Excellence for Translational Omics at RUMC TML |
2019-04-16 |
| Cevec–SEVERAL: investment, 201904 financing round Series D from new + existing investors |
2019-04-16 |
| Univ Nijmegen–Bruker Corp: mass spectrometer, 201904c supply acquisition of timsTOF Pro IM-MS system by RUMC TML |
2019-04-16 |
| Gilead–Novo Group: drug development, 201904– collab clinical research for NASH combining semaglutide + cilofexor + firsocostat Novo Nordisk |
2019-04-12 |
| Evotec–Indivumed: cancer drug discovery, 201904– collab strategic precision medicine for new colorectal cancer drugs |
2019-04-11 |
| Immunic–Needham: investor conference, 201904 supply service Immunic presents at Annual Needham Healthcare Conference in NY |
2019-04-10 |
| DKSH–Bruker Corp: analytical instruments, 201904– distribution excl extension for Bruker AXS products by DKSH in China |
2019-04-09 |
| Probiodrug–SEVERAL: investment, 201904 private placement €8.2m with 4.1m new shares at €2m led by Claus Christiansen et al. |
2019-04-09 |
| AgomAb Therapeutics–SEVERAL: investment, 201904 financing round Series A €21m co-led by V-Bio Ventures + Advent France Biotechnology |
2019-04-03 |
| Bayer–Editas Medicine: genome editing + cell therapy, 201904– strategic research collab + cross-license CRISPR + iPSC technologies BlueRock Tx |
2019-04-03 |
| Dyne Therapeutics–SEVERAL: investment, 201904 financing round Series A $50m from founding investor Atlas Venture plus Forbion + MPM Capital |
2019-04-03 |
| LabCorp–Qiagen: molecular companion diagnostics, 201904– collab LabCorp joins Qiagen’s Day-One Lab Readiness program |
2019-04-03 |
| Rave LLC–Bruker Corp: investment, 201904 acquisition €na by Bruker |
2019-04-03 |
| Chr Hansen–Lonza: live biotherapeutics, 201904– collab establishment 50/50 joint venture for developing + manufacturing microbiome treatments |
2019-04-02 |
| Khloris Biosciences–Bayer: investment, 201904 seed financing €na from Leaps by Bayer |
2019-04-02 |
| Polyneuron–SEVERAL: investment, 201903 financing round Series A CHF22.5m led by Sofinnova Partners + incl NEA |
2019-03-28 |
| Menarini–Curetis: molecular diagnostics, 201903– distribution excl long-term of Unyvero platform + cartridges in Europe by Menarini Diagnostics |
2019-03-26 |
| Hookipa–SEVERAL: investment, 201903– IPO $84m+$12.6m with 6m+900k shares common stock at Nasdaq Global Select Market |
2019-03-22 |
| Atlatl–Miltenyi Biotec: CliniMACSProdigy platform, 201903– collab co-founding of Atlatl-Macs Center for Gene + Cell Therapy in Shanghai |
2019-03-20 |
| Protagen–Oncimmune: investment, 201903 acquisition of Portagen for up to £4.11m in up to 2.636m ordinary shares |
2019-03-19 |
| Merck (DE)–Iktos: drug discovery services, 201903– collab using AI technology for small molecule drug discovery projects |
2019-03-14 |
| Bruker Corp–Cowen: investor conference, 201903 supply service Bruker presents at Cowen & Co Annual Health Care Conference 2019 |
2019-03-12 |
| NovaGo Therapeutics–SEVERAL: investment, 201903 financing round Series A CHF10m co-led by Pureos Bioventures + Neurimmune |
2019-03-04 |
| General Electric–Danaher: investment, 201902– acquisition $21.4b in cash of biopharma business of GE Life Sciences ANNOUNCED |
2019-02-25 |
| Symrise–SEVERAL: investment, 201902 capital increase €400m with 5.614m new shares at €71.25/share to fund acquisition of ADF/IDF |
2019-02-08 |
| Apceth–Hitachi: investment, 201901–201904 acquisition €75.5m 100% of Apceth Biopharma GmbH from Apceth GmbH by Hitachi Chemical |
2019-01-31 |
| Dewpoint Therapeutics–SEVERAL: investment, 201901 financing round Series A $60m led by Polaris Partners |
2019-01-30 |
| MAB Discovery–BioNTech: investment, 201901–201903 acquisition €na of Antibody Generation Unit of MAB Discovery by BioNTech |
2019-01-23 |
| CRISPR Therapeutics–Minapharm: gene transfer technology, 201901– collab + license €na with ProBioGen to develop in vivo delivery technology for CRISPR |
2019-01-22 |
| Exscientia–SEVERAL: investment, 201901 financing round Series B $26m incl Celgene Corp + GT Heallthcare Capital Partners + Evotec |
2019-01-07 |
| Loxo Oncology–Lilly: investment, 201901–201902 acquisition cash tender offer $8b for $235/share |
2019-01-07 |
| N-of-One–Qiagen: investment, 201901 acquisition €na of N-of-One Inc by Qiagen |
2019-01-07 |
| Roche–Exscientia: drug discovery software, 201901– collab up to CHF67m + royalties using Centaur Chemist to design drug candidates |
2019-01-07 |
| Biogen–C4 Therapeutics: neurological drugs, 201901– collab strategic up to $415m upfront/milestones discovery small molecues for protein degradation |
2019-01-04 |
| Biogen–Skyhawk Therapeutics: neurological drugs, 201901– collab strategic $74m upfront + milestones discovery small molecues using SkySTAR platform |
2019-01-04 |
| Ribon Therapeutics–SEVERAL: investment, 201901 financing round Series B $65m led by Novartis Venture Fund |
2019-01-04 |
| Sophia Genetics–SEVERAL: investment, 201901 financing round $77m incl new + lead investor Generation Investment Management LLP |
2019-01-04 |
| CARB-X–Germany (govt): grant, 201901–202212 BMBF commits €40m over 4 years |
2019-01-01 |
| Mestrelab Research–Bruker Corp: investment, 201812 acquisition of majority share €na by Bruker incl strateg collab + partnership |
2018-12-13 |
| Santhera–SEVERAL: investment, 201812 capital increase CHF23.5m with 3.134m shares at CHF7.5/share |
2018-12-12 |
| Argenx–JnJ: investment, 201812 investment $200m of 1.767m new shares at €100.02/share representing 4.68% shareholding by JJDC |
2018-12-03 |
| JnJ–Argenx: cusatuzumab, 201812– collab + license agreem ww with Cilag GmbH for up to $1.6b incl $300m upfront cash |
2018-12-03 |
| Quarton International–Cowen: investment, 201811–201901 acquisition of Quarton by Cowen |
2018-11-20 |
| Omeicos–SEVERAL: investment, 201811 financing round Series C €17m led by new investor Forbion |
2018-11-02 |
| Q-Bioanalytic–Eurofins: investment, 201811 acquisition by Eurofins |
2018-11-01 |
| Endocyte–Novartis: investment, 201810– acquisition $2.1b in cash of Endocyte by Novartis ANNOUNCED |
2018-10-18 |
| LaVision BioTec–Miltenyi Biotec: investment, 201810 acquisition of LaVision BioTec GmbH by Miltenyi |
2018-10-12 |
| Gotham Therapeutics–SEVERAL: investment, 201810 financing round Series A $54m co-led by Versant Ventures + Forbion + SR One |
2018-10-10 |
| Sphingotec–SEVERAL: investment, 201810 financing round €20m co-led by HBM + Wellington Partners |
2018-10-08 |
| ATAI Life Science–SEVERAL: investment, 201810 1st financing round €21.2m from private investors |
2018-10-01 |
| Novaliq–Hopp Group: investment, 201810 financing round €44.9m from Dievini Hopp BioTech Holding GmbH |
2018-10-01 |
| Tusk Therapeutics–Roche: investment, 201809 acquisition for €70m cash + €585m milestones with some assets spun out into Black Belt Therapeutics |
2018-09-28 |
| CRISPR Therapeutics–SEVERAL: investment, 201809 public offering $200m net $185.7m with 4.21m common shares at $46.5/share |
2018-09-19 |
| Roche–Affimed: antibody cancer drug, 201808– collab $96m ufpront + $5b milestones + royalties using ROCK platform to develop ABs with Genentech |
2018-08-27 |
| NuGen–Tecan: investment, 201808 acquisition $54.5m in cash by Tecan |
2018-08-16 |
| Oncologie–Mologen: lefitolimod, 201808–201811 term sheet for acquisition of ww rights to lefitolimod by Oncologie TERMINATED 11/18 |
2018-08-15 |
| United Kingdom (govt)–Bruker Corp: NMR technology, 201808 supply £20m NMR technology to 8 UK universities funded by EPSRC + BBSRC + MRC +NERC |
2018-08-06 |
| Foundation Medicine–Roche: investment, 201806–201807 acquisition all remaining shares for $2.4b in cash at $137/share |
2018-06-19 |
| Sanofi–Evotec: investment, 201806–201807 acquisition integration of Sanofi’s infectious disease RnD in Lyon into Evotec |
2018-06-15 |
| Andrew Alliance–SEVERAL: investment, 201806 financing round Series C $14m incl Tecan + Waters + Inpeco + Rancilio Cube + Sam Eletr + Omega Funds |
2018-06-12 |
| Andrew Alliance–Tecan: investment, 201806 financing round Series C totalling $14m incl Tecan Group |
2018-06-12 |
| Roche–Microbiotica: microbiomics, 201806– collab multi-year up to $534m r+d + commerc of markers + targets + treatments for IBD w Genentech |
2018-06-06 |
| Roivant–Oxford BioMedica: Parkinson’s gene therapy, 201806– license ww excl to OXB-102 $30m upfront + $812.5m milestones to Axovant Sciences |
2018-06-06 |
| Gilead–Hookipa: therapeutic vaccine technology, 201806– collab + license $10m upfront r+d immunotherapies against HIV + HBV |
2018-06-05 |
| Evotec–I’rom Group: iPSC technology, 201805– license non-excl for iPSCs produced with Sendai virus vector technology from ID Pharma |
2018-05-23 |
| Bluebird Bio–Medigene: TCR technology, 201805– collab strategic alliance expansion incl $8m one-time payment |
2018-05-14 |
| Armo BioSciences–Lilly: investment, 201805– acquisition $1.6b cash tender offer at $50/share by Eli Lilly |
2018-05-10 |
| InflaRx–SEVERAL: investment, 201805 primary public offering $51m+$7.65m w 1.5m+225k common shares at $34/share |
2018-05-02 |
| Crescendo Biologics–SEVERAL: investment, 201805 financing round Series B €57m led by Andera Partners |
2018-04-30 |
| Novartis–Pear Therapeutics: digital health, 201804– collab developm + commercialisation of prescripition digital therapeutics for drug abuse Sandoz |
2018-04-18 |
| DKSH–Bruker Corp: analytical instruments, 201804– distribution multi-product line of Bruker AXS in KR + AU + NZ + SG + ID by DKSH Technology |
2018-04-17 |
| Knauer–Microsaic: mass spectrometry, 201804– collab integration of Microsaic’s compact MS techn in Knauer’s LC platform |
2018-04-12 |
| Roivant–Arbutus Biopharma: RNA drugs, 201804– collab founding of jv Genevant Sciences to develop RNA drugs using LNP technology |
2018-04-11 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
Date![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px](/banner/iito-20181119-600-060-lse-life-sciences-europe-com.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
